Form 8-K - Current report:
SEC Accession No. 0001193125-25-065564
Filing Date
2025-03-27
Accepted
2025-03-27 16:35:35
Documents
15
Period of Report
2025-03-25
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d945354d8k.htm   iXBRL 8-K 33485
2 EX-99.1 d945354dex991.htm EX-99.1 6902
6 GRAPHIC g945354g0327010416551.jpg GRAPHIC 3143
  Complete submission text file 0001193125-25-065564.txt   176537

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA bmea-20250325.xsd EX-101.SCH 2866
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE bmea-20250325_lab.xml EX-101.LAB 18738
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE bmea-20250325_pre.xml EX-101.PRE 11718
17 EXTRACTED XBRL INSTANCE DOCUMENT d945354d8k_htm.xml XML 3760
Mailing Address 900 MIDDLEFIELD ROAD 4TH FLOOR REDWOOD CITY CA 94063
Business Address 900 MIDDLEFIELD ROAD 4TH FLOOR REDWOOD CITY CA 94063 (650) 980-9099
Biomea Fusion, Inc. (Filer) CIK: 0001840439 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40335 | Film No.: 25779981
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)